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Chemo-immunotherapy regimens such as fludarabine, cyclo-
phosphamide and rituximab (FCR), and bendamustine-ritux-
imab (BR) have long been mainstays of therapy in chronic
lymphocytic leukemia (CLL). However, in the past decade,
recognition of the role of the microenvironment in the
pathogenesis of CLL led to the development of targeted
inhibitors of the B-cell receptor signaling-associated kinases.1
This resulted in a paradigm shift in treatment of CLL patients
and significantly improved the natural history of the disease.
The seminal paper published by Woyach et al from the Alliance
for Clinical Trials in Oncology Cooperative Group further
highlights the importance of targeted therapy in CLL.2 This
randomized study of ibrutinib, a Bruton tyrosine kinase
inhibitor, used as a single-agent or in combination with
rituximab versus BR in patients ≥65 years old demonstrated a
progression-free survival (PFS) benefit of a targeted agent over a
commonly used standard chemo-immunotherapy in the front-
line setting. While this study did not show an overall survival
(OS) benefit, the results will impact CLL treatment practice on a
global scale as ibrutinib continues to emerge as the preferred
first-line therapy in older patients with CLL, independent of
genetic risk features. This is not the first published evidence of
ibrutinib superiority over chemotherapy. In the RESONATE-2
study, ibrutinib resulted in improved PFS and OS over
chlorambucil in older patients,3 leading to its regulatory
approval in the frontline setting in CLL.
Despite the advance of ibrutinib over chemo-immunotherapy
in high-risk patients, several study details are worth highlighting.
Importantly, not every patient may be ideally suited for frontline
ibrutinib therapy, as the current standard of care has been to
continue treatment indefinitely until progression or intolerance.
In several studies, includingWoyach et al, approximately 20% of
patients discontinue the drug because of adverse events, even
higher in real world analyses. Moreover, patients with
comorbidities have been poorly represented on many clinical
trials to date and are more likely to experience both dose
reductions and interruptions, leading to shortened PFS and OS.4
Treatment with ibrutinib does not mitigate infectious risks, as up
to 20% of patients on this study experienced grade ≥3 infectious
complications, comparedwith 15%with BR. Aspergillus remains
a problem.5 In addition, there were 4 instances of intracranial
hemorrhage with ibrutinib, including 1 death.
Cardiovascular complications of ibrutinib have also been
noteworthy. While less than 8% of patients experienced atrial
fibrillation in this study, the incidence approaches 14% in a
pooled analysis over a similar follow-up period.6 In addition,
ventricular arrhythmias and sudden cardiac death have been
described in ibrutinib-treated patients and this remains an
unpredictable and potentially catastrophic event.7,8 Of note, in
the current study, 12% to 13% of patients died of treatment-
related side effects in the ibrutinib arms, compared with 9% on
the control arm. Of 361 patients who received ibrutinib, 11
sustained ‘unwitnessed’ or unexplained deaths, including ‘sudden
death’, ‘cardiac arrest’, ‘heart failure’ and ‘myocardial infarction’
over a follow-up period of 32 months. Only 2 such deaths
occurred with 176 patients treated with BR. These unexpected
and unpredictable cardiac toxicities should weighed when
considering ibrutinib in frontline therapy of CLL. Meanwhile,
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BR remains an effective regimen, particularly in patients with
favorable disease genetics, and has a lower rate of grade ≥3 non-
hematologic adverse events (63% vs 74%) compared to the
ibrutinib arms in the Woyach et al study. Lastly, the financial
impact of incorporating novel agents into the front-line setting
should not be ignored as more widespread use of these drugs
dramatically raises the cost of managing CLL for both the society
and individual.9 Given the above reservations, we suggest that the
days of chemo-immunotherapy are not yet over.
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